Abstract:Abstract Objective: This retrospective comparative study was aimed to make a comparison between Teriparatide and Zoledronic Acid to provide evidence for the sequential treatment of multiple vertebral fractures caused by osteoporosis of postmenopausal women.Methods: A sum of 106 post-menopausal women undergoing non-operative treatment for recent multiple osteoporotic vertebral fractures between April,2015 and June,2019 were reviewed retrospectively. 44 patients had a treatment of subcutaneous injection of 20 micrograms teriparatide once a day (TPTD group), while 62 patients received 5 mg of zoledronic acid given by an intravenous (IV) infusion once a year (ZOL group). The assessment methods included the general information of patients, the number of new fractures and changes in bone turnover markers, bone mineral density(BMD), back pain and health-related quality of life.Results: Teriparatide was more effective than zoledronic acid in reducing the risk of new vertebral fractures. The lumbar spine BMD rosed significantly in either treatment groups relative to the baseline (P＜0.05). However, the TPTD group increased more than the ZOL group. The hip joint BMD also increased significantly in all groups between months 0 and 12 relative to the baseline（P＜0.05）, no significant differences were found between the changes of two groups after 6 months, but the TPTD group was significantly higher than the ZOL group at 12 months（P＞0.05). In the TPTD group, the values of TP1NP increased 55.9% and 70.8% from baseline(71.69±33.45ng/ml P＜0.05). The values of β-CTX increased from baseline(0.807±0.657ng/ml) to (0.842±0.528)ng/ml at 6 months and the value got back to the baseline at 12 months after the TPTD used. In the ZOL group, the values of TP1NP and β-CTX decreased significantly compared with baseline (69.55±39.15ng/ml, 0.691±0.456ng/ml) 6 months after treatment, which were (33.19±16.81)ng/ml and (0.422±0.267)ng/ml respectively（P＜0.05. No significant changes were found 12 months after treatment compared with the conditions of 6 months(P＞0.05). In both TPTD and ZOL treatment groups, there were significant and clinically relevant improvements in back pain as well as health-related quality of life indicators compared with baseline. Conclusions: TPTD is more advantageous in reducing new fractures, increasing lumbar spine and hip joint BMD and reducing patients' back pain compared with ZOL. TPTD significantly increased marker of bone formation along with slightly increased marker of bone resorption, while ZOL decreased them. This provides a theoretical basis for the apply of Zoledronic acid after discontinuation of teriparatide.

Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study

Effect of Teriparatide on Bone Mineral Density and Fracture in Postmenopausal Osteoporosis: Meta-Analysis of Randomised Controlled Trials

Comparison Of Teriparatide And Zoledronic Acid In Post-Menopausal Women With Multiple Osteoporotic Vertebral Fractures

Real-life effects of pharmacological osteoporosis treatments on bone mineral density by quantitative computed tomography

Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss after Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study

Osteoprotegerin deficiency attenuates the dual effect of strontium on bone

Artificial neural network analysis of bone quality DXA parameters response to teriparatide in fractured osteoporotic patients

Effectiveness of teriparatide in in improving healing rates and bone-turnover markers of osteoporotic hip fracture: a meta-analysis

3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate

The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosis

Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA‐HD Study Extension

Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial

Impact of Teriparatide and Denosumab on Clinical and Radiographic Outcomes in Osteoporotic Vertebral Compression Fractures

Effects of Zoledronic Acid on Bone Mineral Density Around Prostheses and Bone Metabolism Markers after Primary Total Hip Arthroplasty in Females with Postmenopausal Osteoporosis

Effects of Zoledronic Acid Treatment on Fracture Healing, Morbidity and Mortality in Elderly Patients with Osteoporotic Hip Fractures

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial

Effects of zoledronic acid and tibolone on bone mineral density, indexes of bone metabolism, and the risk of fracture in patients with postmenopausal osteoporosis

Influence of bone densitometry on the anti-osteoporosis treatment after fragility hip fracture

470 Changes in CT Hounsfield Unit and T Score Before and After Osteoporosis Treatment With Teriparatide or Denosumab

The effect of osteoporotic treatment on the functional outcome, re-fracture rate, quality of life and mortality in patients with hip fractures: a prospective functional and clinical outcome study on 520 patients

Zoledronic Acid for Periprosthetic Bone Mineral Density Changes in Patients With Osteoporosis After Hip Arthroplasty—An Updated Meta-Analysis of Six Randomized Controlled Trials